T he viral oncogene latent membrane protein 1 (LMP1) plays an essential role in the pathogenesis of a number of EBV-associated malignancies, including nasopharyngeal carcinoma (NPC) endemic in southern China and Taiwan (1) . LMP1 demonstrates oncogenicity through promotion of cell transformation, survival, and invasion (1) (2) (3) . Furthermore, it enhances the production of angiogenic factors and the in vivo formation of the neovasculature for rapid tumor cell expansion and metastasis (1) . Intriguingly, LMP1 can also modulate immune genes related to inflammation and Ag presentation (4, 5) , which may not only facilitate tumor progression (4) but also put the cells at risk for immune exposure and tumor rejection (6) . This finding reveals a crucial role for the in vivo immunogenicity of LMP1 in tumor promotion, especially in cancers such as NPC that arise in the immunocompetent host. Indeed, LMP1-specific CD4 and CD8 T cell responses have been described in healthy virus carriers and cancer patients (7) (8) (9) (10) . However, the potential clinical benefits of anti-LMP1 immunity against LMP1-expressing tumors remain to be elucidated.
Natural LMP1 variants exist in the human population (11, 12) , each possessing different degrees of immunogenicity (13, 14) . Among them, LMP1 derived from Taiwanese NPC (N-LMP1; 1510-LMP1) is a variant prevalent in Taiwanese NPC patients with a characteristic 10-aa deletion of Asian variants and additional multiple point mutations different from the Chinese CAO strain (11) . N-LMP1 has been demonstrated to be highly oncogenic, using cell lines such as BALB/c-3T3 and NPC-TW01 (15, 16) . However, the immunogenicity of N-LMP1 and its relationship to in vivo tumorigenesis remain largely unknown. Considering the involvement of LMP1 in tumor angiogenesis, a prerequisite for tumor progression (17) , we explored the possibility that the im-munogenicity of N-LMP1 may play an important role in immune surveillance against tumor neovessel formation.
To achieve our goal, we evaluated the immunogenicity of N-LMP1 by examining its ability to induce tumor rejection in a transplantable mouse tumor model established by N-LMP1-transformed BALB/c-3T3 (3T3/N-LMP1) cells (18) . Tumor single cells (TSCs) prepared from N-LMP1 tumor tissue were irradiated and used to immunize mice before tumor challenge. To study the immune impact during tumor angiogenic transition to exponential growth, we used a series of noninvasive dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to assess tumor neovascularization (19) and further confirmed the vascular alteration by histologic study and vascular count. The roles of CD4 and CD8 T cells in immune rejection were further analyzed by in vivo depletion and adoptive transfer. The identification of and immunization with an N-LMP1-derived peptide was pursued to verify the induction of antiangiogenic N-LMP1-specific T cell response in vivo.
Materials and Methods

Mice
Male BALB/c, BALB/cAnN nude, and SCID mice were purchased from the National Laboratory Animal Breeding and Research Center (Nangang, Taiwan). IFN-g-deficient mice (C57BL/6 background) from The Jackson Laboratory (Sacramento, CA) were fully backcrossed to the BALB/c mice background for 12 generations before use. All mice were maintained under specific pathogen-free conditions in the Animal Care Center of ChangGung University and were used at the age of 6-10 wk. The experiments were conducted with the approval of the Chang-Gung University Animal Ethics Committee and the Institute of Animal Care and Utilization Committee.
Tumor cell lines
The N-LMP1 (clone 1510)-transformed BALB/c-3T3 (3T3/N-LMP1) stable clones E2 and E9, and 3T3/Neo cells containing the vector alone, were established and maintained as previously described (15, 18) . The E2-plus tumor cell line was recovered and established from an E2 tumor (18) . The Ras oncogene-transformed BALB/c-3T3 (3T3/Ras) clone LZEJ was a gift from Dr. Wen-Chang Lin (20) (Institute of Biomedical Sciences, Academia Sinica, Taiwan). CT26/N-LMP1 and CT26/Neo cells are CT26 cells (a mouse colon carcinoma cell line) that were transfected with the N-LMP1 gene or vector alone, respectively (21) . B95.8 is an EBVtransformed lymphoid cell line that secretes LMP1-containing exosomes (22, 23) .
N-LMP1 tumor model
A transplantable N-LMP1 tumor model was established via the oncogenicity of N-LMP1, as previously described (18) . Briefly, tumors were initiated in SCID mice by 3T3/N-LMP1 and subsequently transferred into BALB/c mice by fragment transplantation. The tumors were passaged among BALB/c mice every 3-4 wk to maintain the tumor line in vivo. The day of transplantation was referred to as day 0. The tumor volumes were measured with a caliper and calculated using the following formula: volume = d 1 3 d 2 3 d 3 3 0.5236, where d n represents the three orthogonal diameter measurements. A tumor with a minimal size of 40 mm 3 was scored as positive.
Preparation of TSCs, immunization, and tumor challenge
TSCs were prepared by enzyme digestion of the tumor mass as previously described (18) . The 3T3/Ras TSCs were from LZEJ-induced tumors (10 6 per mouse). For immunization, 4000 R-irradiated (Gammacell 3000 Elan, MDS Nordion, Ottawa, ON, Canada) TSCs, 3T3/Neo cells (2 3 10 6 per mouse), or peptide-loaded dendritic cells (DCs) (1 3 10 6 per mouse) were injected s.c. into the right flank of the mice. At 4 d later, mice were contralaterally challenged with N-LMP1 (E2) tumor fragment. Alternatively, CT26 tumors were induced by s.c. injection of CT26/N-LMP1 or CT26/Neo cells (2 3 10 5 per mouse), respectively.
Magnetic resonance imaging
MRI experiments were performed on a horizontal 7.0 T Pharma Scan 70/16. Experimental procedures and imaging data acquisitions were carried out according to our previous study (19) . In brief, imaging was performed on days 3, 7, 9, 11, and 14 after tumor transplantation. A 38-mm birdcage coil was used for radiofrequency excitation and signal reception, and no triggering was used for data acquisition. To generate T2 maps and determine tumor volume, multislice multiecho axial images were acquired using standard spin-echo sequences with a repetition time (TR) of 5000 ms; echo times (TEs) of 10. (24) . In this analysis, the rate of contrast agent uptake, dCt(t)/dt, can be determined by the product of the permeability (P) and surface area (S), the tracer concentration in arterial blood plasma (Cp), the tracer concentration in tissue (Ct), and the leakage space per unit volume of tissue (ve), according to the following equation:
where K trans is equal to PS. The dynamic signal-enhanced curve was fitted on a pixel-by-pixel basis using nonlinear regression analysis to yield a parametric map of K trans .
Tumor histology and quantitation of neovessels
Tumor paraffin sections (5 mm) were stained with H&E, using the standard procedures. To quantify the tumor neovessels, mice were anesthetized by the i.p. injection of tribromoethanol [(Avertin), 660 mg/kg; Sigma-Aldrich, St. Louis, MO] and perfused transcardially with PBS buffer for 2 min, followed by 10% India ink/gelatin solution for 20 s. The solution was freshly prepared by mixing India ink solution (Creative Microbiologicals, Taipei, Taiwan) with 50-60˚C preheated 2% gelatin (25) . The rate of perfusion was 6 ml/15 s. Afterward, the mice were placed on ice for 30-60 min to allow solidification of the gelatin before tumor removal for cryostat sectioning at 10 mm. Whole tissue sections were imaged by HistoFAXS (TissueGnostics, Vienna, Austria) using a Zeiss microscope at a 3200 final magnification. The images were further processed to improve the blackand-white contrast, and the black areas were quantified using ImageJ software. The average of the three largest tumor areas per tumor was given.
In vivo depletion and enrichment of CD4 and CD8 T cells
For in vivo depletion of CD4 or CD8 T cells, the mice were i.p. injected with the mAbs GK1.5 (rat IgG 2b ) or 2.43 (rat IgG 2b ) over 3 successive days (25 ml ascites per mouse per day). Vaccination was conducted 1 d later. For adoptive transfer or in vitro T cell activation, splenic CD4 or CD8 T cells were positively selected using magnetic separation (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. The in vivo depletion of CD4 or CD8 T cells and the purity of T cell subpreparations were confirmed using flow cytometric analysis, which showed .90% specific depletion and .90% purity of the enrichments.
Flow cytometric analysis
Cells were washed with cold FACS buffer (1% FCS-PBS) and stained with fluorescein-labeled mAb according to the manufacturer's protocol. The cells (10 4 per sample) were analyzed on a FACScan cytometer using CellQuest software. In all cases, cells were gated according to size and scatter to eliminate debris.
Preparation of N-LMP1-presenting DCs and MHC-II + stromal cells
DCs were prepared as previously described, with modification (26). In brief, normal spleens were fragmented and enzyme digested, followed by NycoPrep 1.077 fractionation. CD11c + cells in the low-density fraction were positively selected using an autoMACS Separator (Miltenyi Biotec). In some experiments, the low-density cells were sorted for CD45 
CD4 T cell stimulation and IFN-g assay
DCs were mixed with primed CD4 T cells at a 1:4 DC/T cell ratio in a total volume of 200 ml. Supernatants were collected at 72 h for the measurement of IFN-g, using the DuoSet ELISA kit (R&D Systems, Minneapolis, MN). An anti-IE d mAb was purchased from Abcam (Cambridge, U.K.).
Immunoblot analysis
Cultured cells were lysed in Nonidet P-40 lysis buffer, and equal amounts of protein were separated by NaDodSO 4 -PAGE and transferred to polyvinylidene fluoride membranes. After blocking with 5% BSA (SigmaAldrich), membranes were probed with primary Abs against LMP1 (S12) (1:2000), HSP70 (1:2000) (System Biosciences, Mountain View, CA), CD81 (1:2000) (System Biosciences), or GAPDH (1:3000) (Abcam), followed by incubation with HRP-conjugated secondary Ab and development with ECL detection reagents.
Exosome isolation and transfer
Cells were cultured in complete DMEM at a density of 1 3 10 6 cells per 10 ml for overnight. The media were replaced with serum-free DMEM for 48 h. The culture supernatants were then collected for total exosome isolation, using the ExoQuick-TC kit (System Biosciences) according to the manufacturer's instructions (27) . The isolated exosome pellets were either lysed in 100 ml 1% Nonidet P-40 lysis buffer for immunoblot analysis or resuspended in 100 ml PBS and stored at 280˚C until use. B95.8 cells, with or without 12-O-tetradecanoylphorbol-13-acetate (TPA) (Sigma-Aldrich) (30 ng/ml) treatment, were used as LMP1 positive controls (22) . For exosomal uptake, purified MHC-II + cells (10 6 ) were coincubated with 50 ml exosomes at 37˚C for time points indicated. Afterward, cells were stringently washed with PBS, and total proteins were collected for the immunoblot analysis.
Angiogenesis assay
In vivo angiogenesis assays were conducted by injecting 0.3 ml growth factor-reduced Matrigel containing 2 3 10 5 MHC-II + stromal cells. At 8 d after implantation, the blood flow in the Matrigel implants was visualized and measured by high-resolution ultrasound microimaging using the VEVO 2100 Ultrasound with a 40-MHz transducer in three-dimensional power Doppler mode (VisualSonics, Toronto, ON, Canada). The percentage of the Matrigel implant volume with detectable blood flow was calculated using the three-dimensional segmentation tool in the VEVO 2100 software package (28) . Afterward, the Matrigel implants were harvested for histologic examination by H&E staining.
Statistical analysis
Data are presented as the mean values 6SD. Statistics were evaluated using a two-tailed test. A p value , 0.05 was considered statistically significant.
Results
The induction of early tumor angiogenic arrest by immunization
To examine the in vivo immunogenicity of N-LMP1, BALB/c mice were immunized with PBS or irradiated N-LMP1-containing TSCs (N-LMP1) prepared from a tumor that was induced by the 3T3/ N-LMP1 stable clone E2. The nontumorigenic 3T3/Neo (Neo) were injected to serve as a 3T3 cell background control. At 4 d later, the mice were challenged with an E2 tumor by the implantation of a tumor fragment on day 0. To assess the kinetics of immune rejection, tumor development was observed by MRI because of its high resolution (19) . Fig. 1A demonstrates a detectable gradual increase of tumor volume in days 3-14 of the PBS and Neo groups. However, tumor growth was retarded in the N-LMP1 group. Previously, we identified an angiogenic time window (days 7-14) accompanying this mild tumor expansion, using volume transfer constant (K trans ) analysis of DCE-MRI (19) . To understand the influence of immunization on the early angiogenesis that precedes N-LMP1 tumor exponential growth after day 14 (18, 19) , we evaluated the temporal change of K trans in mice receiving PBS or N-LMP1 in the immunization. The temporal K trans maps and corresponding direct photographs are shown in Fig. 1B . The K trans maps of the PBS group illustrated that leaky vessels developed from the tumor periphery on day 3 and rapidly penetrated the whole tumor within 2 wk. However, high K trans values were absent in the N-LMP1 group. Quantitative analysis of the temporal changes in the spatial dependence of K trans profiles within the tumor is shown in Fig. 1C . The PBS group simultaneously developed multiple peaks with rising K trans values during tumor expansion, indicating that multiple angiogenic active sites are merging together during early neovascularization. However, these angiogenic activities were suppressed by a previous immunization.
The tumor neovasculature in day 7 tumor tissues in the PBS and N-LMP1 groups was next examined histologically. As shown in Fig. 2A , control PBS-treated tumors contained blood vessels with irregular diameters and branches distributed within the tumor tissue that was newly grown from the implanted tumor fragment. Patches of hemorrhage were seen in the tumors of the N-LMP1 group of mice, suggesting vascular damage resulting from immune surveillance. To further quantify the angiogenic activity, blood vessels were labeled in vivo with India ink by perfusion (Fig. 2B) . The images of black-filled dots and strips in frozen sections were further processed and quantified using ImageJ software. Fig. 2C illustrates a significantly lower number of blood vessels in the N-LMP1 group tumors than in control tumors, confirming that immunization reduced tumor angiogenesis.
The immunogenicity of N-LMP1
To further determine the immunogenicity of N-LMP1 responsible for successful immunization, mice were immunized with PBS, irradiated 3T3/Neo cells, 3T3/Ras TSCs, and 3T3/N-LMP1 TSCs (from clone E2-or E9-induced tumor) 4 d before E2 tumor challenge on day 0. As indicated in Fig. 3A , tumors developed in all of the control mice, with exponential growth occurring after day 14. Whereas all of the mice receiving 3T3/Neo and 3T3/Ras TSCs also developed tumors, tumor growth was inhibited in E2 or E9 TSC-immunized mice. The result suggested that the immunogenicity of N-LMP1 caused effective tumor rejection in vivo.
Because NPC-derived LMP1 variants were notable for their nonimmunogenicity or low immunogenicity (13, 14) , the N-LMP1-induced protective effect along the extending period of time elapsed after immunization was verified next (Fig. 3B) . The mice receiving immunization from 4 to 28 d prior to tumor challenge exhibited varying degrees of tumor inhibition. Among these animals, both day (24) and day (27) groups had full protection, indicating that N-LMP1 could indeed induce an antitumor response, which was optimal 4-7 d after administration.
The T cell immunity induced by N-LMP1
The in vivo immunogenicity of an Ag relies on both the Ag itself and the immune responsiveness of the host (29) . To examine the protective role of T cells, we verified the immune effect in nude mice (Fig. 4A) . In contrast to BALB/c mice, nude mice immu-nized with either PBS or N-LMP1 developed tumors, suggesting that T cell competency is required to protect against N-LMP1 tumors. The important T cell subset (CD4 or CD8) in BALB/c mice responsible for tumor rejection was next examined by in vivo depletion using specific Abs prior to the immunization and tumor challenge. Fig. 4B demonstrates full protection in the absence of CD8 T cells. However, the protection was completely abolished when CD4 T cells were depleted (Fig. 4C) , indicating an essential role for CD4 T cells in the tumor defense demonstrated.
Owing to the nontumorigenic property of 3T3/Neo, we used a colon cancer CT26 tumor system in BALB/c mice to further validate the induction of CD4 T cell immunity by N-LMP1 independent of the CD8 T cell response. SCID mice underwent adoptive transfer with normal CD4 or CD8 T cells prior to CT26/ N-LMP1 tumor challenge. Fig. 5A illustrates that only mice receiving CD4 T cells showed tumor growth inhibition, indicating that they were the effectors. Because IFN-g is essential in CD4 T cell-mediated antitumor immunity (30-32), CD4 T cells from IFN-g-deficient mice were also transferred into SCID mice and compared with normal CD4 T cells. The inability of IFN-g 2/2 CD4 T cells to inhibit tumor progression (Fig. 5A) suggested that the N-LMP1-induced CD4 T cell immunity was also mediated by IFN-g. To verify that the induction of the CD4 T cell response was specific to N-LMP1, another set of SCID mice was challenged with CT26/ Neo tumor cells with or without CD4 T cell transfer (Fig. 5B) . CT26/Neo tumor growth was not attenuated by CD4 T cell transfer. These results suggest a direct link between N-LMP1 immunogenicity and CD4 T cell-mediated host immune defense.
Mapping of CD4 T cell response to N-LMP1 peptide
To further validate the induction of CD4 T cell immunity by N-LMP1, we evaluated the N-LMP1 responsiveness of primed CD4 T cells in vitro. CD4 T cells from N-LMP1-immunized mice were restimulated with DCs precultured with or without dead E2-plus cells that provided the N-LMP1 Ag. To facilitate the T cell IFN-g response, we treated DCs with LPS and polyinosinic-polycytidylic acid after the E2-plus coculture for optimal IL-12 production. The supernatants of the CD4 T-DC coculture were tested for IFN-g release by ELISA. Fig. 6A shows that primed CD4 T cells produced little IFN-g. The addition of DCs enhanced IFN-g production, and N-LMP1-preloaded DCs further boosted the response, suggesting that the N-LMP1 activated CD4 T cells in vivo.
To locate the regions of CD4 T cell recognition, eight candidate peptides in the N-LMP1 sequence predicted to bind to mouse MHC-II molecules were synthesized and tested in vitro for their ability to stimulate primed CD4 T cells using peptide-pulsed DCs. 
The antitumor effect of N-LMP1 peptide-loaded DCs in vivo
As in vitro activated DCs may stimulate CD4 T nonspecifically (Fig. 6A) , we verified the antitumor function of N-LMP1 [186] [187] [188] [189] [190] [191] [192] [193] [194] in vivo. Normal mice were immunized with DCs alone or with control peptide N-LMP1 1-10 -or N-LMP1 186-194 -loaded DCs 4 d before challenge by tumor fragment transplantation (Fig. 6D) . Tumor development was suppressed only in mice immunized with DC/N-LMP1 [186] [187] [188] [189] [190] [191] [192] [193] [194] , confirming the ability of N-LMP1 to induce specific CD4 T cell responses.
The potential target of N-LMP1-specific CD4 T cells CD4 T cells may be stimulated by tumor cells that express MHC-II. As the MHC-II expression may be induced by IFN-g, we examined MHC-II on tumor cells by flow cytometry, using CT26/N-LMP1 or E2-plus cells that had been cultured with or without IFN-g for 2 d (Fig. 7A) . Neither cell line exhibited MHC-II even with IFN-g stimulation. Alternatively, T cells may recognize stromal cells that present tumor Ags captured from surrounding cancer cells (33) . We have demonstrated that infiltrates bearing CD11b, a marker for the myeloid monocytic lineage of cells, are abundant in N-LMP1 tumor (18) . To evaluate the potential recognition of stromal cells by N-LMP1-specific CD4 T cells, TSCs were examined for the expression of MHC-II and CD11b by flow cytometry. MHC-II expression was mainly associated with CD11b + cells (Fig. 7B) . Next, the MHC-II + cells were sorted and analyzed for IFN-g production by CD4 T cells primed by N-LMP1 186-194 -loaded DCs (Fig. 7C) . The IFN-g production was significantly higher in the coculture than in CD4 T or MHC-II + cells alone, suggesting the in vivo presentation of N-LMP1 Ag by tumorsurrounding MHC-II + cells. Tumor cells carrying latent EBV were shown to release exosomes containing LMP1 (34) . To further assess the possibility of intercellular transfer of N-LMP1 from tumor to stromal cells, we examined the LMP1 protein in exosomes purified from the culture supernatants of 3T3/Neo or 3T3/N-LMP1 cells in comparison with the whole-cell lysates, using immunoblot analysis. The relative levels of LMP1 expression were compared with an EBV-positive cell line, B95.8, that secretes LMP1-containing exosomes (22, 23) . As shown in Fig. 7D, B95 .8 cells treated with TPA for 48 h exhibited increased LMP1 levels in both cell lysates and exosomes, as expected. Although LMP1was undetectable in either preparation derived from 3T3/Neo cells, it was abundant in 3T3/N-LMP1 counterparts. The standard exosomal markers HSP70 and CD81 were detected in all exosome preparations. Thus, 3T3/N-LMP1 resembles EBV-harboring tumor cells, releasing exosomes containing abundant LMP1 protein. Next, the potential for internalization of exosomes by MHC-II + stromal cells was evaluated by coculturing MHC-II + cells with 3T3/Neo-or 3T3/N-LMP1-derived exosomes for 1 or 3 h. Following extensive cell washing, cell lysates were prepared and examined for LMP1 protein by immunoblotting. As shown in Fig. 7E, LMP1 was detected only in MHC-II + cells exposed to purified exosomes secreted from 3T3/N-LMP1, but not from 3T3/Neo, cells. The results suggest that MHC-II + cells can uptake LMP1-containing exosomes and that LMP1 Ag is likely to be transferred from tumor cells to neighboring MHC-II + stromal cells through mechanisms such as uptake of exosomes.
To obtain further evidence for the role of CD4 T cells in the control of tumor neovascularization, we conducted an in vivo Matrigel angiogenesis assay stimulated by MHC-II + stromal cells. The MHC-II + cells were sorted, mixed with Matrigel, and injected (s.c.) into mice receiving PBS or N-LMP1 immunization 4 d before. The vascularization in the Matrigel implants was assessed 8 d later by ultrasonography and further confirmed by histologic examination (Fig. 7F) . Compared with the PBS group, which exhibited vascularization of the Matrigel implants, a significantly lower degree of vascularity was observed in the N-LMP1 group (Fig. 7F, 7G) . Altogether, these results suggest that N-LMP1-specific CD4 T cells may target angiogenic stroma independently of direct attack against tumor cells. 
Discussion
The oncogenicity of N-LMP1 is crucial for NPC development in Taiwan (11) . The aim of this study was to explore the effect of its in vivo immunogenicity on the course of N-LMP1-directed tumor progression. We used a tumor model that was established by in vivo tumorigenesis of N-LMP1-transformed BALB/c-3T3 cells in syngeneic immunocompetent hosts (18) , highlighting the interaction between N-LMP1 and the immune system during tumor progression. Using an immunization approach, we demonstrated for the first time, to our knowledge, N-LMP1-mediated induction of an antiangiogenic response in CD4 T cells, providing important insights into the in vivo role of anti-LMP1 T cell immunity in EBV-associated malignancies.
Our data suggest that N-LMP1 may bear immunogenicity in addition to oncogenicity (15) . This finding is consistent with a previous clinical study that LMP1-positive tumors exhibit a faster expansion pattern, but a lower frequency of recurrence and metastasis, compared with LMP1-negative tumors (35) . However, using an experimental mouse model, several reports have described the nonimmunogenicity or low immunogenicity of NPCderived LMP1 variants (13, 14) . This discrepancy may be a result of the different LMP1 sequences and the genetic backgrounds in the cell lines and mouse strains used in the studies. Nevertheless, despite the fast and profound antitumor immunity elicited by N-LMP1, the response does not seem to be sustained following immunization (Fig. 3B) . The decline of the tumor-free rate with time suggests that the immunosuppressive properties demonstrated by other NPC-derived LMP1 variants (13, 14, 36, 37) may still be preserved in N-LMP1. However, the regulatory T cell response is eventually induced (38) , creating an immunogenic window in the early exposure of N-LMP1 to the immune system. CD8 T cells have been considered the main effectors that protect against LMP1-associated malignancies (9) , with little attention paid to relating CD4 responses. Our major finding is that the N-LMP1-specific CD4 T cells have an effector role in monitoring tumor neovascularization. Intriguingly, the current study (Fig. 5) , as well as others (29, 33, 39, 40) , showed that normal CD4 T cells are involved in tumor prevention. This finding agrees with our previous observation that a naive host could reject a tumor in-duced by monosuspended tumor cells (18) . However, this defense may target early events, becoming insufficient against more advanced stages, owing to the high rate of tumor incidence displayed in mice receiving tumor fragment transplantation (18) . It appears that tumor fragment provides stroma that favors tumor development (41) . Nevertheless, we showed that the protumor condition could be neutralized (42) via immunization that generates IFN-gproducing CD4 T effectors blocking angiogenesis. As N-LMP1 tumor does not express MHC-II even with IFN-g stimulation (Fig. 7) , it is unlikely that the diminishing angiogenesis is caused by direct recognition and killing of tumor cells by CD4 T cells (39, 40) . Tumor-infiltrating macrophages have been shown to play an Ag-presenting role in an MHC-II-negative tumor model (39) . In our model system, the major infiltrating cells are CD11b-positive myeloid cells (18) . It has been demonstrated that the recruitment of these cells into the tumor microenvironment is crucial for de novo vessel formation and angiogenic switch (43) . Consistent with this idea, we also observed early stepwise deposits of myeloid cells close to the vessel lumen (44) , and the timeline of deposition matches the timeline of the multiple high K trans peaks developing from day 7 to day 14 ( Fig. 1) . In this study, we further demonstrated that the majority of CD11b + stromal cells express MHC-II. Moreover, they can uptake LMP1 released by tumor cells via exosomes, which may have facilitated the acquisition of the LMP1 Ag by stromal cells for CD4 T cell recognition. Although N-LMP1 could not be detected in MHC-II + cells (as shown in the control group with 3T3/Neo exosomes, Fig. 7E ), their ability to present the N-LMP1 Ag is revealed by the stimulation of IFN-g production in N-LMP1 186-194 -loaded DC-primed CD4 T cells (Fig. 7C) . Immunization with N-LMP1 186-194 -pulsed DCs successfully inhibited tumor progression (Fig. 6D) , further supporting the natural processing and presentation of N-LMP1 protein by tumor tissues to CD4 T cells. More importantly, we showed that the MHC-II + cells can stimulate vascularization. By contrast, the activity is dampened in the immune host, confirming that N-LMP1-specific CD4 T cells target MHC-II + stromal cells in the angiogenic control. Our results support the importance of IFN-g in CD4 T-mediated angiogenic blockade. IFN-g may impair tumor neovascularization by alteration of endothelial cell function (45) , modulation of proinflammatory microenvironment (31, 46) , and/or disruption of the angiogenic process involving stromal cells that bear IFNRs (32) .
The more prominent role of CD4 than CD8 T cells may be inferred from the prior activation of CD4 T, which is in general required for CD8 T activation. It is likely that the control of early tumor angiogenesis demands early T cell infiltration (30, 31) . Nevertheless, CD4 T cell response may lead only to tumor dormancy (31) . The successive infiltration of CD8 T cells may be necessary to sustain long-term immune protection (33, 47) , providing an explanation for the slightly less powerful tumor inhibition on day 28 in the SCID mice receiving only CD4 T cell transfer (Fig. 5) . Recently, some proangiogenic myeloid stromal cells have been shown to uptake and cross-present tumor Ags via the MHC-I molecule, leading to an antitumor CD8 T cell response, including the prevention of neovascularization through cell elimination (33) . It is worth noting that the stromal cells identified by the MHC-I-restricted TCR tetramer are also MHC-II positive (48) , implying the possibility of recognizing common stromal cells in the collaboration of CD4 and CD8T cells during the process of angiogenic surveillance.
Our results demonstrate that N-LMP1 bears immunogenicity, inducing an IFN-g-mediated CD4 T cell surveillance against tumor angiogenesis. This potential clinical benefit provides a rationale for the use of LMP1-based immunotherapy for cancer treatment (6, 49, 50) . This study also demonstrates the antigenic and angiogenic activity of the MHC-II + stromal cells, thus supporting therapies such as the emerging T cell therapy that targets tumor stroma (33, 51) .
